Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease.

Details

Serval ID
serval:BIB_7A7C72F36E10
Type
Autre: use this type when nothing else fits.
Collection
Publications
Institution
Title
Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease.
Author(s)
Visser P.J., Reus L.M., Gobom J., Jansen I., Dicks E., Tsolaki M., Verhey FRJ, Popp J., Martinez-Lage P., Vandenberghe R., Lleó A., Molinuevo J.L., Engelborghs S., Freund-Levi Y., Froelich L., Sleegers K., Dobricic V., Hong S., Lovestone S., Streffer J., Vos SJB, Bos I., Smit A.B., Blennow K., Scheltens P., Teunissen C.E., Bertram L., Zetterberg H., Tijms B.M.
Issued date
03/11/2020
Language
english
Abstract
Alzheimer's disease (AD) is characterised by abnormal amyloid beta and tau processing. Previous studies reported that cerebrospinal fluid (CSF) total tau (t-tau) levels vary between patients. Here we show that CSF t-tau variability is associated with distinct impairments in neuronal plasticity mediated by gene repression factors SUZ12 and REST. AD individuals with abnormal t-tau levels have increased CSF concentrations of plasticity proteins regulated by SUZ12 and REST. AD individuals with normal t-tau, on the contrary, have decreased concentrations of these plasticity proteins and increased concentrations in proteins associated with blood-brain and blood CSF-barrier dysfunction. Genomic analyses suggested that t-tau levels in part depend on genes involved in gene expression. The distinct plasticity abnormalities in AD as signaled by t-tau urge the need for personalised treatment.
Pubmed
Create date
19/01/2021 20:05
Last modification date
13/04/2024 7:04
Usage data